BIOFILCHEM 72 TGT 90+ SL - Return Risk - RR Timeframe < 6M NSE:BIOFILCHEM Buy Recommended Can hold for long term Shared with 💚 By Rachit Sethia
Eris Lifesciences Ltd. is presently engaged in manufacturing and marketing of pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this, it has a portfolio of 112 Mother Brands across therapy areas. Eris Lifesciences Ltd CMP is...
The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below the support zone & the lower trendline. The target is placed near resistance.
The stock has reached lower trendline and may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below support zone & the lower trendline. The target is placed near resistance. Market is bearish, so take positions carefully.
ERIS Life Sciences was first given at 644 it went upto 861.95 and has corrected substantially there after. Fresh entry above 734 closing Targets 768. 768 will be a major resistance. Crossing 768 the price can go to 795 and 815 levels. Thus X/2 entry can be taken in the counter at 734 closing and X/2 after closing above 768. Stop Loss should be at closing below 670.
The stock has reached lower trendline and may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby. Risk Reward Ratio - 2:1 SL is placed below support zone & the lower trendline. The target is placed near resistance.
ERIS Lifescience is trying to create a symmetric triangle pattern in 6 months timeframe and can possibly give a breakout in upward side considering the pharma sector still has a pending bull run. One can take a long position from 517 - 524 for a possible breakout. Targets should be - 546 - 588 - 588++
PLEASE SEE CHART FOR DETAILS TARGET 1 : 650 TARGET 1 : 700 STOP LOSS : 520 **These are my personal observations. Please trade at your own risk.**
Eris Lifesciences has been forming a continuation pennant pattern. MACD supports the statement. [8} Next target 10%